ProCE Banner Activity

CME

Expert Perspectives on Biosimilar Agents

In this video module, a multidisciplinary panel of expert faculty discuss the use of biosimilars across oncology, rheumatology, dermatology, and gastroenterology specialties.

This program is divided into four segments. After clicking the Launch buttons below, the player will open in a new window. If it doesn’t appear, please disable your pop-up blocker and try again.

Physicians : maximum of 1.50 AMA PRA Category 1 {Credits}

Released: November 16, 2017

Expiration: November 15, 2018

No longer available for credit.

Share

Faculty

Andrew M. Evens

Andrew M. Evens, DO, MSc, FACP

Professor and Chief
Division of Hematology/Oncology
Tufts Medical Center
Boston, Massachusetts

Jonathan Kay

Jonathan Kay, MD

Professor of Medicine and Population and Quantitative Health Sciences
Timothy S. and Elaine L. Peterson Chair in Rheumatology
Division of Rheumatology
Department of Medicine
University of Massachusetts Medical School
Physician
Division of Rheumatology
Department of Medicine
UMass Memorial Medical Center
Worcester, Massachusetts

Alan C. Moss

Alan C. Moss, MD

Associate Professor of Medicine
Department of Gastroenterology
Harvard Medical School
Boston, Massachusetts

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an independent educational grant from

Boehringer Ingelheim

Target Audience

This program is intended for rheumatologists, dermatologists, gastroenterologists, oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals interested in biosimilars.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Explain the similarities and differences between biosimilars, reference biologics, and small molecule generics
  • Compare available safety and efficacy data for available biosimilars and reference biologics and the potential impact of interchangeability, extrapolation of indications, and substitution on dose/response, adverse events, and clinical outcomes
  • Summarize the key steps outlined by the FDA to demonstrate biosimilarity between a biosimilar and its reference biologic
  • Compare the regulatory approval pathway between a small molecule generic, reference biologic and a biosimilar

Faculty Disclosure

Primary Author

Andrew M. Evens, DO, MSc, FACP

Professor and Chief
Division of Hematology/Oncology
Tufts Medical Center
Boston, Massachusetts

Andrew M. Evens, DO, MSc, FACP, has disclosed that he has received consulting fees from Seattle Genetics and Takeda, fees for non-CME/CE services from Celgene, and funds for research support from Seattle Genetics and Takeda.

Jonathan Kay, MD

Professor of Medicine and Population and Quantitative Health Sciences
Timothy S. and Elaine L. Peterson Chair in Rheumatology
Division of Rheumatology
Department of Medicine
University of Massachusetts Medical School
Physician
Division of Rheumatology
Department of Medicine
UMass Memorial Medical Center
Worcester, Massachusetts

Jonathan Kay, MD, has disclosed that he has received consulting fees from Amgen, Boehringer Ingelheim, Bristol‐Myers Squibb, Janssen, Lilly, Merck, Pfizer, Roche, Samsung Bioepis, Sandoz, and UCB and funds for research support paid to his institution from AbbVie, Genentech, Lilly, Pfizer, and UCB.

Alan C. Moss, MD

Associate Professor of Medicine
Department of Gastroenterology
Harvard Medical School
Boston, Massachusetts

Alan C. Moss, MD, has disclosed that he has received consulting fees from Boehringer Ingelheim, Gilead Sciences, Janssen, Pfizer, and Seres.

Staff Disclosure

Staff

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 16, 2017, through November 15, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this multidisciplinary activity is to provide clinicians in the most relevant specialties—rheumatology, dermatology, gastroenterology, and oncology—with both broad and specialty-specific perspectives on biosimilars.